http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
류마티스관절염과 골관절염 환자에 대한 쎄레콕시브의 유효성과 안전성
성상석 ( Sang Seokg Seong ),박용범 ( Yong Beom Park ),엄완식 ( Wan Sik Uhm ),이지수 ( Ji Soo Lee ),지종대 ( Jong Dae Ji ),배상철 ( Sang Cheol Bae ) 대한류마티스학회 2006 대한류마티스학회지 Vol.13 No.3
Objective: The aim of this study was to define the efficacy and safety of celecoxib in Korean patients with rheumatoid arthritis and osteoarthritis. In addition, the impact of gastrointestinal symptom severity on health related quality of life (HRQoL) was measured before and after the treatment with celecoxib. Methods: Three hundred seventy nine patients with rheumatoid arthritis (n=175) and osteoarthritis (n=204) were enrolled from 25 centers from May 2004 to December 2004. After treatment of celecoxib for 4 weeks, efficacy was determined by physician`s global assessment and EQ-5D. Severity of gastrointestinal (GI) symptom was assessed by visual analogue scale. Results: Treatment made improvement in 263 patients (69.4%), but 108 patients (28.5%) didn`t show change in their symptom and 8 patients (2.1%) were aggravated after treatment. Mean change was 0.129±0.3 in EQ-5D utility score (p<0.05), 11.8±17.8 in VAS in EQ-5D (p<0.05) and -7.9±19.6 in GI symptom severity (p<0.05). Blood pressure was not elevated after treatment and there was no cardiovascular adverse event. Gastrointestinal symptom improvement correlates with improvement in VAS (r=0.2, p<0.01). Conclusion: Celecoxib is not only effective in patients with rheumatoid arthritis and osteoarthritis but also helpful in reducing GI symptom.
사이클로포스파마이드 치료 후 심한 백혈구감소증을 보인 Cytochrome P450 2A6*1B 변이형을 가진 환자
성상석 ( Sang Seokg Seong ),윤재희 ( Jae Hee Yun ),김은영 ( Eun Young Kim ),신재국 ( Jae Gook Shin ),전재범 ( Jae Bum Jun ),배상철 ( Sang Cheol Bae ) 대한류마티스학회 2007 대한류마티스학회지 Vol.14 No.2
Cyclophosphamide, a prodrug requiring metabolic activation by cytochrome P450 (CYP) enzymes, is used widely for proliferative lupus nephritis and various CYP isoenzymes have been demonstrated to be involved in the bioactivation of cyclophosphamide in humans, including CYP2A6, 2B6, 2C19, 2C9, 3A4, and 3A5. The response or adverse event after intravenous cyclophosphamide pulse therapy in lupus nephritis patient seems to be different for each individual and genetic polymorphism of CYP may explain the difference. Generally, wild types of CYP seem to be more active in the activation of cyclophosphamide than variant types of CYP. Here, we report a case of lupus nephritis with a genotype of CYP2A6*1B who suffered from severe leukopenia after intravenous cyclophosphamide pulse therapy.
한국인에서 EQ-5D를 이용한 건강 관련 삶의 질 측정
성상석 ( Sang Seokg Seong ),최찬범 ( Chan Bum Choi ),성윤경 ( Yoon Kyoung Sung ),박용욱 ( Yong Wook Park ),이혜순 ( Hae Soon Lee ),엄완식 ( Wan Sik Uhm ),김태환 ( Tae Whan Kim ),전재범 ( Jae Bum Jun ),유대현 ( Dae Hyun Yoo ),이오 대한류마티스학회 2004 대한류마티스학회지 Vol.11 No.3
Objective: There has been no data on health related quality of life (HRQOL) in general Korean population. Assessing factors affecting HRQOL in Koreans is fundamental in HRQOL research. The objective of this study is to assess HRQOL in Korean using Korean version of EQ-5D (KEQ-5D). Methods: HRQOL was assessed using KEQ-5D from 1,044 randomly selected population representing general Korean population with telephone interview Result: The mean KEQ-5D utility score in Korean was 0.88 (range: -0.59∼1.00). Sociodemographic data showed relatively higher score in male, younger, well educated, higher income, and white color people. Among a variety of diseases, gastric ulcer/gastritis, arthritis, hypertension diabetes, low back pain were common in Korea. The most significant chronic diseases influencing Koreans were gastrointestinal disorder and arthritis. Conclusion: This paper suggests basic information on HRQOL in Korean and can be a useful parameter in comparison in the future research.